PENTIXAPHARM HOLDING N AG Asset Resilience Ratio
PENTIXAPHARM HOLDING N AG asset resilience ratio. PENTIXAPHARM HOLDING N AG (PTP) has an Asset Resilience Ratio of 0.82% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PENTIXAPHARM HOLDING N AG defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of PENTIXAPHARM HOLDING N AG (2023–2025)
Asset resilience ratio of PENTIXAPHARM HOLDING N AG from 2023 to 2025. This chart shows how PENTIXAPHARM HOLDING N AG's Asset Resilience Ratio has changed over time. Read PTP current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down PENTIXAPHARM HOLDING N AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see PENTIXAPHARM HOLDING N AG assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €342.00K | 0.82% |
| Total Liquid Assets | €342.00K | 0.82% |
Asset Resilience Insights
- Limited Liquidity: PENTIXAPHARM HOLDING N AG maintains only 0.82% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
PENTIXAPHARM HOLDING N AG Industry Peers by Asset Resilience Ratio
Compare PENTIXAPHARM HOLDING N AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
PENTIXAPHARM HOLDING N AG Asset Resilience Ratio by Year (2023–2025)
PENTIXAPHARM HOLDING N AG asset resilience ratio by year from 2023 to 2025. The table below shows the annual Asset Resilience Ratio data for PENTIXAPHARM HOLDING N AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.82% | €342.00K ≈ $399.83K |
€41.86 Million ≈ $48.94 Million |
+0.09pp |
| 2023-12-31 | 0.72% | €531.00K ≈ $620.79K |
€73.40 Million ≈ $85.81 Million |
-- |
About PENTIXAPHARM HOLDING N AG
Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 binding, peptide-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunologic… Read more